3'-UTR, 3'-untranslated region; ADAM17, a disintegrin and metalloprotease 17; APCs, antigen-presenting cells; AREs, adenylate and uridylate (AU)-rich elements; ATF3, activating transcription factor 3; CD273/274, cluster of differentiation 273/274; CDK4, cyclin-dependent kinase 4; CMTM6, CKLF like MARVEL transmembrane domain containing 6; CSN5, COP9 signalosome subunit 5; CTLs, cytotoxic T lymphocytes; EMT, epithelial to mesenchymal transition; EpCAM, epithelial cell adhesion molecule; Exosome; FACS, fluorescence-activated cell sorting; GSDMC, Gasdermin C; GSK3ß, glycogen synthase kinase 3 beta; HSF1, heat shock transcription factor 1; Hi-C, high throughput chromosome conformation capture; ICB, immune checkpoint blockade; IFN, interferon; IL-6, interleukin 6; IRF1, interferon regulatory factor 1; Immune checkpoint blockade; JAK, Janus kinase 1; NFκB, nuclear factor kappa B; NSCLC, non-small cell lung cancer; OTUB1, OTU deubiquitinase, ubiquitin aldehyde binding 1; PARP1, poly(ADP-ribose) polymerase 1; PD-1, programmed cell death-1; PD-L1; PD-L1, programmed death-ligand 1; PD-L2; PD-L2, programmed death ligand 2; Post-transcriptional regulation; Post-translational regulation; SP1, specificity protein 1; SPOP, speckle-type POZ protein; STAG2, stromal antigen 2; STAT3, signal transducer and activator of transcription 3; T2D, type 2 diabetes; TADs, topologically associating domains; TFEB, transcription factor EB; TFs, transcription factors; TNFα, tumor necrosis factor-alpha; TTP, tristetraprolin; Topologically associating domain; Transcription; UCHL1, ubiquitin carboxy-terminal hydrolase L1; USP22, ubiquitin specific peptidase 22; dMMR, deficient DNA mismatch repair; irAEs, immune related adverse events